Skip to main content
. 2020 Jan 13;13:323–335. doi: 10.2147/OTT.S226770

Figure 6.

Figure 6

Validation of key genes and pathways in breast cancer. (A) Expression level of key genes in MCF-7and MDB-MA231 cancer cells. (B) The correlation of expression level of ERLIN2 and survival. (C) Validation of knockdown efficiency by RT-PCR. (D and E) The proliferation of MCF-7 and MDA-MB231 cells after transfected with Si-ERLIN2 or control. (F) The apoptosis of MCF-7 and MDA-MB231 cells after transfected with Si-ERLIN2 or control analyzed by flow cytometry. (G) Statistical analysis of the rate of apoptosis cells after transfected with Si-ERLIN2 or control. (H and I) Invasion assay analysis of MCF-7 cells after transfected with Si-ERLIN2 or control. (J and K) Wound healing assay analysis of MCF-7and MDA-MB231 cells after transfected with Si-ERLIN2 or control. (L) Total protein expression of PI3K and p-PI3K in MCF-7 and MDA-MB231 cells analyzed by Western blot. Results are representative of three independent experiments. (**P <0.01, ***P <0.001, ****P <0.0001).